



# 5 ways to think differently about cancer immunotherapy

Using immunotherapies for the treatment of cancer is not a new concept, but recent advances in the field have encouraged us to think differently about how they are applied in the treatment of cancer.

**1** Cancer immunotherapy is no longer just about boosting the body's immune system, it's more specific. Immunotherapy does **not** begin/end with **just one target/pathway**




**Some targets on cancer cells** act as immune system 'stop' signs that may be blocked




**Other targets on immune cells** may promote an anti-cancer immune response that was weak or non-existent before


**2** Immunotherapies do not always have to work alone. In fact, **combining** different classes of **medicines may be very important**. Combinations that might synergise with immunotherapies include:



**Other immunotherapies**




**Targeted therapies**



**Chemotherapies**


**3** **Antibodies** can now be **re-engineered** in way to enhance the body's immune system to fight cancer by:



**Disabling the antibody's capacity** to launch an immune attack on healthy cells




**Attaching biological 'beacons'** that attract the immune system to cancer cells




**Bringing together cancer and immune cells** with 'bi-specific' antibody binding

**4** Cancer immunotherapy can be **personalised** to a person's individual tumour biology



Immunotherapies are often designed for use in **broad populations**



In some cases **biomarkers and diagnostics** can help us identify who will more likely have a clinically meaningful benefit

**5** In order to advance cancer immunotherapy to where it is today, a **change in mindset** has been adopted, including:



**Expansion of large phase I trials** with potential for registration and basket trials with multiple expansion cohorts



**Validation of diagnostic tests** as early as possible in clinical trials



**Fostering of open and frequent dialogue** between companies and regulatory authorities (e.g., breakthrough therapy designation)